Table of Contents

In Fill Finish (FF) you will find representatives of the world’s top sterile filling operations developing solutions to some of the most intractable technical and regulatory challenges.  Members are now rolling out industry approaches to environmental monitoring and particle risk management; working together on rapid micro adoption and reconciling some of the critical challenges that Annex 1 brings to final filtration integrity testing and isolator disinfection.

The FF mission is to develop and implement best practice processes in drug product operations.

 FF  collaborates to develop and implement safe, predictable, lean and agile processes in drug product operations that biopharmaceutical pipelines need now and into the future and  has strong representation of the top sterile filling operations in the world, both drug manufacturers and CMOs.

Phorum members have shared goals

  • Agree how to demonstrate control levels to agencies, in an effective way
  • Move new techniques forward in our risk averse environment
  • Work together to develop error proof, highly flexibility operations

The current FF collaboration program is targeting a number of transformational operational improvements.  While some of these benefits are easy gains for members, they also recognize that in our regulated environment it makes sense to move together.  For this reason, in many cases companies plan synchronized adoption to change the landscape that regulators see across the industry in one go.

Benefits include:

  • Reducing barrier breaks and isolator operating costs by optimizing settle plate use and even replacement with new rapid micro technologies.
  • Harmonizing on the best biopharmaceutical Environmental Monitoring (EM) deployment practices, to ensure the very best control and investment profile in existing and new facilities
  • Reducing lyophilization scale-up and transfer times, and allowing for better optimization of run times and capacity by making the application and use of lyo computer models a reality at commercial scale
  • Reducing particle contamination of conventional elastomeric stoppers, by promoting a strong industry voice and engaging with suppliers and other parties in a constructive way
  • Providing clarity and confidence on particle classification by product type for visual inspection operations, with the use of a new harmonized risk based methodology.

Share This

Share this post with your friends!